Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc.

These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Imunon, Inc. (NASDAQ:IMNN) ...

Shares of NVIDIA Corporation NVDA rose sharply in today's pre-market trading after the company posted first-quarter results. The company reported first-quarter revenue of $44.1 billion, up 69% ...

Imunon, Inc. (NASDAQ:IMNN) has completed a private placement, securing $3.25 million in initial funding by selling 7,222,223 ...

In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate ...

LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously ...

The company reported quarterly earnings of 30 cents per share, which beat the Street estimate of 26 cents. Quarterly revenue ...